Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Gyan

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|January 17, 2016
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosisEmmanuel Gyan, Valérie Andrieu, Alessandro Sanna, et al.
Bone Marrow Transplantation|October 8, 2021
Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
British Journal of Haematology|June 21, 2021
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life studyThibault Comont, Mathieu Meunier, Amina Cherait, et al.
Bone Marrow Transplantation|May 24, 2020
Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Hematological Oncology|July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network studyNadia Younan, Carole Soussain, Sylvain Choquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trialGandhi Damaj, Rémy Gressin, Krimo Bouabdallah, et al.
Blood|October 25, 2017
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphomaThierry Lamy, Gandhi Damaj, Pierre Soubeyran, et al.
Haematologica|February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|January 17, 2016
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosisEmmanuel Gyan, Valérie Andrieu, Alessandro Sanna, et al.
Bone Marrow Transplantation|October 8, 2021
Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
British Journal of Haematology|June 21, 2021
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life studyThibault Comont, Mathieu Meunier, Amina Cherait, et al.
Bone Marrow Transplantation|May 24, 2020
Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Hematological Oncology|July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network studyNadia Younan, Carole Soussain, Sylvain Choquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trialGandhi Damaj, Rémy Gressin, Krimo Bouabdallah, et al.
Blood|October 25, 2017
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphomaThierry Lamy, Gandhi Damaj, Pierre Soubeyran, et al.
Haematologica|February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
Pageof 18